RNLS and cancer: Given observations that monoclonal antibodies raised against a strongly evolutionarily conserved domain of the RNLS protein, the RP220 peptide, are potent inhibitors of cancer cell proliferation [2, 3], we assessed the potential for RP220 to be an antigenic target for T cells, using the above bioinformatics (in silico), CDR3 chemical complementarity scoring approaches.